International Isotopes begins thallium production

Article

Radiopharmaceutical manufacturer International Isotopes has begun producing thallium 201 at both its completed linear accelerator and its cyclotron facilities in Denton, TX. The firm expects that the production of thallium at both facilities will allow

Radiopharmaceutical manufacturer International Isotopes has begun producing thallium 201 at both its completed linear accelerator and its cyclotron facilities in Denton, TX. The firm expects that the production of thallium at both facilities will allow it to provide an ample supply of the isotope to hospitals and clinics in the U.S. Since it is situated near two airports, International Isotopes can ship isotopes with short half-lives overnight, according to Dr. Ira Lon Morgan, chairman and CEO. Thallium has a half-life of 73 hours and is used for the diagnosis of heart disease.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.